WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H314220
CAS#: 236395-14-5
Description: Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine.The European Medicines Agency (EMA) has recommended granting marketing authorization in 2009 for adjunctive therapy for partial-onset seizures, with or without secondary generalisation, in adults with epilepsy. (Source: http://en.wikipedia.org/wiki/Eslicarbazepine_acetate).
Hodoodo Cat#: H314220
Name: Eslicarbazepine acetate
CAS#: 236395-14-5
Chemical Formula: C17H16N2O3
Exact Mass: 296.12
Molecular Weight: 296.320
Elemental Analysis: C, 68.91; H, 5.44; N, 9.45; O, 16.20
Synonym: BIA 2093; Zebinix; Exalief; Stedesa; Aptiom
IUPAC/Chemical Name: (S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide
InChi Key: QIALRBLEEWJACW-INIZCTEOSA-N
InChi Code: InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
SMILES Code: O=C(N1C2=CC=CC=C2C[C@H](OC(C)=O)C3=CC=CC=C31)N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Eslicarbazepine acetate (BIA 2-093), an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. |
| In vitro activity: | CBZ and eslicarbazepine exhibit similar concentration dependent suppression of epileptiform activity in hippocampal slices. Eslicarbazepine- and LCM-treated fast-inactivated channels recovered similarly to control conditions, whereas CBZ- and OXC-treated channels required longer pulses to recover. Reference: Neuropharmacology. 2015 Feb;89:122-35. https://pubmed.ncbi.nlm.nih.gov/25242737/ |
| In vivo activity: | The antinociceptive effects of orally administered ESL (eslicarbazepine), standard/alternative analgesics, and two-drug ESL-analgesic combinations were examined in the orofacial formalin test in mice. ESL, analgesics, and two-drug ESL-analgesic combinations significantly and dose-dependently reduced nociceptive behaviour in the second, inflammatory phase of the test. Reference: Psychopharmacology (Berl). 2020 May;237(5):1435-1446. https://pubmed.ncbi.nlm.nih.gov/32025776/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 79.5 | 268.29 | |
| Ethanol | 11.0 | 37.12 |
The following data is based on the product molecular weight 296.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Hebeisen S, Pires N, Loureiro AI, Bonifácio MJ, Palma N, Whyment A, Spanswick D, Soares-da-Silva P. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015 Feb;89:122-35. doi: 10.1016/j.neuropharm.2014.09.008. Epub 2014 Sep 19. PMID: 25242737. 2. Pecikoza U, Tomić M, Micov A, Vuković M, Stepanović-Petrović R. Eslicarbazepine acetate interacts in a beneficial manner with standard and alternative analgesics to reduce trigeminal nociception. Psychopharmacology (Berl). 2020 May;237(5):1435-1446. doi: 10.1007/s00213-020-05470-7. Epub 2020 Feb 5. PMID: 32025776. 3. Pecikoza U, Micov A, Tomić M, Stepanović-Petrović R. Eslicarbazepine acetate reduces trigeminal nociception: Possible role of adrenergic, cholinergic and opioid receptors. Life Sci. 2018 Dec 1;214:167-175. doi: 10.1016/j.lfs.2018.10.059. Epub 2018 Oct 27. PMID: 30393024. |
| In vitro protocol: | 1. Hebeisen S, Pires N, Loureiro AI, Bonifácio MJ, Palma N, Whyment A, Spanswick D, Soares-da-Silva P. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015 Feb;89:122-35. doi: 10.1016/j.neuropharm.2014.09.008. Epub 2014 Sep 19. PMID: 25242737. |
| In vivo protocol: | 1. Pecikoza U, Tomić M, Micov A, Vuković M, Stepanović-Petrović R. Eslicarbazepine acetate interacts in a beneficial manner with standard and alternative analgesics to reduce trigeminal nociception. Psychopharmacology (Berl). 2020 May;237(5):1435-1446. doi: 10.1007/s00213-020-05470-7. Epub 2020 Feb 5. PMID: 32025776. 2. Pecikoza U, Micov A, Tomić M, Stepanović-Petrović R. Eslicarbazepine acetate reduces trigeminal nociception: Possible role of adrenergic, cholinergic and opioid receptors. Life Sci. 2018 Dec 1;214:167-175. doi: 10.1016/j.lfs.2018.10.059. Epub 2018 Oct 27. PMID: 30393024. |
1: Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013 Sep;22(7):528-36. doi: 10.1016/j.seizure.2013.03.016. Epub 2013 Apr 25. Review. PubMed PMID: 23623245.
2: Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. Review. PubMed PMID: 22612290.
3: Mauri-Llerda JA. [Eslicarbazepine acetate: a novel therapeutic alternative in the treatment of focal seizures]. Rev Neurol. 2012 May 1;54(9):551-5. Review. Spanish. PubMed PMID: 22532219.
4: Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother. 2012 Apr;13(5):699-715. doi: 10.1517/14656566.2012.667803. Epub 2012 Mar 10. Review. PubMed PMID: 22404663.
5: Falcão A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. CNS Drugs. 2012 Jan 1;26(1):79-91. doi: 10.2165/11596290-000000000-00000. Review. PubMed PMID: 22171585.
6: Chang XC, Yuan H, Wang Y, Xu HQ, Zheng RY. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008907. doi: 10.1002/14651858.CD008907.pub2. Review. PubMed PMID: 22161441.
7: Chung SS, Kelly K, Schusse C. New and Emerging Treatments for Epilepsy: Review of Clinical Studies of Lacosamide, Eslicarbazepine Acetate, Ezogabine, Rufinamide, Perampanel, and Electrical Stimulation Therapy. J Epilepsy Res. 2011 Dec 30;1(2):35-46. eCollection 2011 Dec. Review. PubMed PMID: 24649444; PubMed Central PMCID: PMC3952328.
8: Rauchenzauner M, Luef G. Eslicarbazepine acetate for partial-onset seizures. Expert Rev Neurother. 2011 Dec;11(12):1673-81. doi: 10.1586/ern.11.158. Review. PubMed PMID: 22091592.
9: Owen RT. Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy. Drugs Today (Barc). 2010 Jan;46(1):23-31. doi: 10.1358/dot.2010.46.1.1437709. Review. PubMed PMID: 20200693.
10: Mestre T, Ferreira J. Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. Expert Opin Investig Drugs. 2009 Feb;18(2):221-9. doi: 10.1517/13543780802635107 . Review. PubMed PMID: 19236268.
